On Wednesday, Piper Sandler reiterated its Overweight rating on shares of Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) with a price target of $23.00. The firm's assessment follows the announcement by Evernorth that it will exclude the brand Humira from its Express Scripts (NASDAQ:ESRX) commercial formularies starting in 2025. This decision is expected to benefit Teva's Humira biosimilar, Simlandi, which is included in the Express Scripts formularies.
The analyst at Piper Sandler highlighted the favorable outlook for Teva's U.S. generics and biosimilars business in 2025. This positive projection is supported by Teva's planned entry into the biosimilar Stelara market in February 2025. The firm anticipates that Teva's expanding presence in the biosimilar sector, along with its portfolio of complex small molecule generics, will contribute to the stability of its U.S. business.
Despite acknowledging that competition may lead to a decline in contributions from certain generics, such as the Revlimid generic in 2025, the firm remains confident in Teva's overall growth trajectory. The company's increasing biosimilar footprint is seen as a key factor for maintaining a stable U.S. generics and biosimilars business.
The reiterated Overweight rating and maintained stock price target reflect the firm's belief in the potential growth of Teva's biosimilar product Simlandi, following the strategic move by Evernorth. The analyst's statement underscores the expectation that Teva's U.S. generics and biosimilars business is well-positioned for the future, despite the industry's competitive nature.
InvestingPro Insights
As Teva Pharmaceutical Industries Limited (NYSE:TEVA) navigates the biosimilar market landscape, real-time data from InvestingPro offers additional insights into the company's financial health and market performance.
With a market capitalization of $21.22 billion and a notable gross profit margin of 49.5% over the last twelve months as of Q2 2024, Teva's financial stability is evident. Despite a negative P/E ratio of -46.49, analysts predict the company will turn profitable this year, as reflected by the adjusted P/E ratio of 24.4 for the same period.
InvestingPro Tips highlight Teva's high shareholder yield and its position as a prominent player in the Pharmaceuticals industry. These factors, coupled with a strong return over the last year of 94%, signal investor confidence and a robust market stance. The company's stock is trading near its 52-week high, with a price that is 99.31% of this peak, indicating a large price uptick over the last six months. However, it's worth noting that short-term obligations exceed liquid assets, which could present challenges in immediate financial obligations.
For investors seeking a deeper dive into Teva's performance and potential, additional InvestingPro Tips are available, providing a comprehensive analysis of the company's market outlook. With these insights, investors can make more informed decisions regarding Teva's stock amidst the evolving biosimilar landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.